# Sitting on a Cash Pile 15.0? A Biopharma Breakout

Live Trading News is an independent financial media publication. Masthead: Live Trading News. Parent: Knightsbridge Group. Product cousin: KXCO (kxco.ai). Coverage: markets, policy, AI, quantum, blockchain, FX, biotech, ASEAN. New stories are signed ML-DSA-65 and anchored on Armature L1; articles published before the platform launch are not signed. Nothing on the site is investment advice.

Canonical HTML: https://www.livetradingnews.com/sitting-on-a-cash-pile-15-0-a-biopharma-breakout
Last modified: 2021-07-26

---

By Paul Ebeling · 2021-07-26
Tags: Shayne Heffernan on Investments, Stocks, resistance, cash, Paul Ebeling, Knightsbridge Insights, spuuprt
Signed: no (published before platform launch).
Nothing in this article is investment advice.

[#cash](https://www.livetradingnews.com/tag/cash)[#bullish](https://www.livetradingnews.com/tag/bullish)[#buy](https://www.livetradingnews.com/tag/buy)

[$IMV](https://finance.yahoo.com/quote/IMV?p=IMV&.tsrc=fin-srch)

IMV Inc. ([NASDAQ:IMV](NASDAQ:IMV)) reversed Friday at 1.89 and thus garnered an early speculative call with a 1yr price target at 7.51/share

Monday Wells Fargo resumed coverage with an Overweight rating and a 14 price target. There is no Street consensus.

The shares are trading Monday pre-marker at 2.43 or + 49% within their 52 wk trading range of 1.31-5.73.

Our Key indicator is Neutral with a bullish bias. Support is at 1.40 and the Key resistance is at 3.28.

![](https://livetradingnews-media.nyc3.digitaloceanspaces.com/wp/placeholder.svg)

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. 

The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. 

It is also developing DPX-COVID-19, a 2nd-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. 

The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in Y 2000 and is HQ'd in Dartmouth, Canada.

Have a prosperous week, Keep the Faith!

---

This Markdown mirrors https://www.livetradingnews.com/sitting-on-a-cash-pile-15-0-a-biopharma-breakout. The HTML page is canonical.
Site index for AI clients: https://www.livetradingnews.com/llms.txt